پديد آورندگان :
Rahimi Firoozeh نويسنده , Alipour Fateme نويسنده , Ghazizadeh Hashemi Hassan نويسنده , Hashemian Mohammad-Naser نويسنده , Mehrdad RAMIN نويسنده
چكيده لاتين :
Background: This study was conducted to determine the treatment outcome of incompletely
removed, histopathologically documented ocular surface squamous neoplasia with mitomycin-C.
Methods: Through an interventional case series, 17 eyes of 17 patients presented with
incompletely removed ocular surface squamous neoplasia were treated according to a protocol
using two to three alternate seven-day courses of 0.04% mitomycin-C. Clinical recurrence was retreated
with the same protocol. All patients had weekly follow-up visits to the end of the treatment
course, then biweekly visits for three months, and monthly visits, thereafter.
Results: The mean±SD follow-up period was 30.76±4.4 (range: 24.5 - 41) months. Five patients
(29.4%) experienced recurrence after the initial treatment; four of them responded to retreatment
and were disease-free till the end of follow-up. Survival analysis with Kaplan-Meier method was
performed. Taking into account four recurrences, the 41-month nonrecurrence rate was 70.6%.
However, including four of five patients with recurrence who responded to retreatment, the final
outcome in survival analysis was 94.1% non recurrence for 41 months of follow-up.
All patients reported mild to moderate redness and irritation which were controlled with
lubricants and mild corticosteroid eye drops. No serious ocular or systemic side effects were
observed.
Conclusion: Point zero four percent (0.04%) mitomycin-C drop used as two to three alternate
seven-day courses seems to be a safe and effective treatment for ocular surface squamous
neoplasia.